-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
9,135 Shares in Immunovant, Inc. (NASDAQ:IMVT) Purchased by Prospera Financial Services Inc
9,135 Shares in Immunovant, Inc. (NASDAQ:IMVT) Purchased by Prospera Financial Services Inc
Prospera Financial Services Inc acquired a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Get Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 9,135 shares of the company's stock, valued at approximately $50,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dupont Capital Management Corp bought a new position in shares of Immunovant during the fourth quarter valued at approximately $232,000. Virginia Retirement Systems ET AL lifted its position in shares of Immunovant by 6.2% during the 4th quarter. Virginia Retirement Systems ET AL now owns 78,600 shares of the company's stock valued at $670,000 after acquiring an additional 4,600 shares during the last quarter. Arizona State Retirement System acquired a new stake in shares of Immunovant during the 4th quarter valued at $92,000. Swiss National Bank lifted its position in shares of Immunovant by 17.3% during the 4th quarter. Swiss National Bank now owns 88,700 shares of the company's stock valued at $756,000 after acquiring an additional 13,100 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Immunovant by 136.6% in the fourth quarter. Bank of America Corp DE now owns 225,448 shares of the company's stock valued at $1,921,000 after purchasing an additional 130,142 shares in the last quarter. Institutional investors and hedge funds own 32.53% of the company's stock.
Get Immunovant alerts:Immunovant Stock Down 1.3 %
Shares of IMVT opened at $5.16 on Wednesday. The stock has a market cap of $601.22 million, a price-to-earnings ratio of -3.51 and a beta of 0.94. Immunovant, Inc. has a 12 month low of $3.14 and a 12 month high of $9.53. The company has a 50-day moving average price of $4.13 and a two-hundred day moving average price of $4.85.
Immunovant (NASDAQ:IMVT – Get Rating) last announced its quarterly earnings results on Wednesday, June 8th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.03). Equities research analysts expect that Immunovant, Inc. will post -1.66 EPS for the current fiscal year.Analyst Ratings Changes
IMVT has been the topic of a number of research reports. Robert W. Baird dropped their price target on shares of Immunovant to $6.00 in a research note on Thursday, June 9th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Immunovant in a research report on Thursday, June 9th. Finally, UBS Group reduced their target price on shares of Immunovant to $7.00 in a research note on Friday, May 20th.
Immunovant Company Profile
(Get Rating)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.
Recommended Stories
- Get a free copy of the StockNews.com research report on Immunovant (IMVT)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- CVS and Walgreens Show Why Investment Objectives Matter
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
Want to see what other hedge funds are holding IMVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunovant, Inc. (NASDAQ:IMVT – Get Rating).
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.
Prospera Financial Services Inc acquired a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Get Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 9,135 shares of the company's stock, valued at approximately $50,000.
普罗斯佩拉金融服务公司在第一季度收购了免疫公司(纳斯达克代码:IMVT-GET评级)的新股份,根据该公司在最近提交给美国证券交易委员会的13F文件中的说法。该机构投资者购买了9,135股该公司股票,价值约50,000美元。
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dupont Capital Management Corp bought a new position in shares of Immunovant during the fourth quarter valued at approximately $232,000. Virginia Retirement Systems ET AL lifted its position in shares of Immunovant by 6.2% during the 4th quarter. Virginia Retirement Systems ET AL now owns 78,600 shares of the company's stock valued at $670,000 after acquiring an additional 4,600 shares during the last quarter. Arizona State Retirement System acquired a new stake in shares of Immunovant during the 4th quarter valued at $92,000. Swiss National Bank lifted its position in shares of Immunovant by 17.3% during the 4th quarter. Swiss National Bank now owns 88,700 shares of the company's stock valued at $756,000 after acquiring an additional 13,100 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Immunovant by 136.6% in the fourth quarter. Bank of America Corp DE now owns 225,448 shares of the company's stock valued at $1,921,000 after purchasing an additional 130,142 shares in the last quarter. Institutional investors and hedge funds own 32.53% of the company's stock.
其他机构投资者和对冲基金最近也买卖了该公司的股票。杜邦资本管理公司(DuPont Capital Management Corp)在第四季度购买了新的免疫股票头寸,价值约23.2万美元。弗吉尼亚退休系统公司等人在第四季度将其在免疫系统公司的股票头寸提高了6.2%。弗吉尼亚退休系统等公司在上个季度增持了4600股后,现在拥有该公司7.86万股股票,价值67万美元。亚利桑那州退休系统在第四季度收购了免疫公司的新股份,价值92,000美元。瑞士国家银行在第四季度将其在Immunovant的股票头寸提高了17.3%。瑞士国家银行在上个季度增持了13,100股后,现在持有88,700股该公司股票,价值75.6万美元。最后,美国银行(Bank Of America Corp DE)在第四季度增持了136.6%的Immunovant股票。美国银行DE目前持有225,448股该公司股票,价值1,921,000美元,此前该公司在上一季度又购买了130,142股。机构投资者和对冲基金持有该公司32.53%的股票。
Immunovant Stock Down 1.3 %
免疫类股下跌1.3%
Shares of IMVT opened at $5.16 on Wednesday. The stock has a market cap of $601.22 million, a price-to-earnings ratio of -3.51 and a beta of 0.94. Immunovant, Inc. has a 12 month low of $3.14 and a 12 month high of $9.53. The company has a 50-day moving average price of $4.13 and a two-hundred day moving average price of $4.85.
周三,IMVT的股价开盘报5.16美元。该股市值为6.0122亿美元,市盈率为-3.51倍,贝塔系数为0.94。该公司股价跌至3.14美元的12个月低点和9.53美元的12个月高位。该公司的50日移动均线价格为4.13美元,200日移动均线价格为4.85美元。
Analyst Ratings Changes
分析师评级发生变化
IMVT has been the topic of a number of research reports. Robert W. Baird dropped their price target on shares of Immunovant to $6.00 in a research note on Thursday, June 9th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Immunovant in a research report on Thursday, June 9th. Finally, UBS Group reduced their target price on shares of Immunovant to $7.00 in a research note on Friday, May 20th.
IMVT已经成为许多研究报告的主题。罗伯特·W·贝尔德在6月9日星期四的一份研究报告中将免疫软件的目标股价下调至6.00美元。在6月9日星期四的一份研究报告中,HC Wainwright重申了“买入”的评级,并发布了免疫药物股票16.00美元的目标价。最后,瑞银集团在5月20日星期五的一份研究报告中将其股票的目标价下调至7.00美元。
Immunovant Company Profile
免疫科技公司简介
(Get Rating)
(获取评级)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.
免疫公司是一家临床阶段的生物制药公司,开发用于治疗自身免疫性疾病的单抗。它开发了一种新型的全人类单抗Batotopab,它选择性地结合和抑制新生儿片段结晶受体,该受体正处于治疗重症肌无力和甲状腺眼病的IIa期临床试验,以及治疗温热自身免疫性溶血性贫血的II期临床试验的完成。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Immunovant (IMVT)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- CVS and Walgreens Show Why Investment Objectives Matter
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
- 免费获取StockNews.com关于免疫抗体的研究报告(IMVT)
- 3M、霍尼韦尔、通用电气在季度报告后收购吗?
- 这只国防股票的基本面和技术面都看涨
- CVS和Walgreens展示为什么投资目标很重要
- 索菲金融股票终于准备好为投资者买单了吗?
- 美敦力和直觉外科公司准备实现大增长吗?
Want to see what other hedge funds are holding IMVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunovant, Inc. (NASDAQ:IMVT – Get Rating).
想看看还有哪些对冲基金持有IMVT吗?访问HoldingsChannel.com获取免疫公司(纳斯达克代码:IMVT-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.
接受《免疫新药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收最新新闻和分析师对免疫系统及相关公司评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧